What question did this study set out to answer?

This research aims to investigate the influence of neoadjuvant durvalumab on tumor microenvironment features and their correlation with event-free survival in patients with resectable NSCLC.

May 29, 2026Journal of Clinical Oncology

Impact of neoadjuvant durvalumab (D) on tumor microenvironment (TME) features and their association with event-free survival (EFS) in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.

View Full Paper

Ask AI

Bookmark

Authors

JHJ HeymachThe University of Texas MD Anderson Cancer Center RSRoss StewartAstraZeneca (United Kingdom)DHDavid H. HarpoleDuke Medical Center

Discussion

Member takes

Implication

Randomized trial shows how neoadjuvant durvalumab affects tumor microenvironment and event-free survival in resectable NSCLC, indicating broader implications for treatment.

Key Points

This research aims to investigate the influence of neoadjuvant durvalumab on tumor microenvironment features and their correlation with event-free survival in patients with resectable NSCLC.
Double-blind placebo-controlled study (NCT03800134)
Adults with treatment-naïve resectable NSCLC were randomized to receive neoadjuvant platinum-based chemotherapy with durvalumab or placebo.
Transcriptional analyses conducted on tumor samples collected at baseline and surgery to classify tumor microenvironment features.
Three phenotypic clusters based on TME features were identified at baseline: immune desert (C1), immune suppressed (C2), and immune activated (C3).
Event-free survival at 36 months was significantly different across clusters: C1 (27.8%), C2 (55.7%), and C3 (77.2%).
Neoadjuvant durvalumab was associated with a higher proportion of patients converting to immune-activated phenotypes after treatment.

Cite This Study

Heymach et al. (2026) studied this question.

synapsesocial.com/papers/6a192f1bfab5b468c4418661 https://doi.org/10.1200/jco.2026.44.16_suppl.8015

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial shows how neoadjuvant durvalumab affects tumor microenvironment and event-free survival in resectable NSCLC, indicating broader implications for treatment.

Impact of neoadjuvant durvalumab (D) on tumor microenvironment (TME) features and their association with event-free survival (EFS) in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.

Discussion

Member takes

Implication

Key Points

Cite This Study

Impact of neoadjuvant durvalumab (D) on tumor microenvironment (TME) features and their association with event-free survival (EFS) in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider